MycoWorks Raises $125 Million Series C Financing to Fund Mass Production of Fine Mycelium™

Led by Prime Movers Lab, Financing to Launch MycoWorks' First Full-Scale Production Plant to Meet Demand for Sustainable, Luxury-Quality Leather Alternatives

News provided by

MycoWorks

Jan 13, 2022, 06:00 ET

EMERYVILLE, Calif., Jan. 13, 2022 /PRNewswire/ -- Today, MycoWorks announced a $125M Series C funding round led by Prime Movers Lab, with participation from new investors SK Networks and Mirabaud Lifestyle Impact & Innovation Fund, in addition to other new and existing investors including DCVC Bio and Novo Holdings. The Series C funding round will be used to launch the first full-scale Fine Mycelium™ production plant to meet the growing demand for the company's materials, including MycoWorks' flagship product, Reishi™.

MycoWorks' patented Fine Mycelium process produces natural material with the performance of the finest animal leathers and lower environmental impact. It is a proprietary biotechnology platform that engineers mycelium to grow the only made-to-order, made-to-specification luxury material. Recognized globally as a breakthrough in materials science, Fine Mycelium materials offer superior hand feel, durability, and aesthetics. The process also unlocks new design possibilities for fashion and luxury brands, while its predictable, scalable tray-based process offers much-needed relief to supply chain constraints.

Based in Union County, South Carolina, the new facility is modeled after the company's semi-automated Emeryville pilot plant that successfully demonstrates the scalability of the Fine Mycelium process. In operation for one year, the pilot plant demonstrates high production yields, meeting target costs, and bringing MycoWorks through its latest production milestone of 10,000 trays processed. The new facility, slated to be operational in a year, will enable initial mass-production volumes of several million square feet of Fine Mycelium materials per year. The financing will also support the expansion of the company's fast-growing team as well as continued research, development, and innovation to advance the Fine Mycelium platform.

"We are thrilled to partner with new and returning investors who have deep experience in manufacturing scale-up. MycoWorks' Fine Mycelium platform produces the world's highest-quality, leather-like material via a proprietary process that we own and operate," said Matt Scullin, CEO of MycoWorks. "As the only vertically-integrated biomaterials company in the new materials space, we will use this new capital to continue growing our leadership position."

"What MycoWorks has achieved with its Fine Mycelium platform is not just a breakthrough, it is a revolution for industries that are ripe for change," said David Siminoff, General Partner at Prime Movers Lab. "This opportunity is massive, and we believe that unrivaled product quality combined with a proprietary, scalable manufacturing process has MycoWorks poised to serve as the backbone of the new materials revolution."

"MycoWorks makes the only product that we have found that resembles animal leather's quality, and they are producing it on a highly scalable platform. We are excited to partner to manufacture Fine Mycelium materials on a global scale," said Ho Jeong Lee, Executive Vice President of SK Networks.

Refined over the course of two decades of research and development, Fine Mycelium offers brands' creative teams unprecedented levels of input and design at the material level. Brands can select and customize the thickness, weight, hand, and drape of Fine Mycelium materials. Using its highly controlled, tray-based system, Fine Mycelium engineers mycelium as it grows to exact specifications to create perfectly uniform, high-quality sheets at scale. Vertically integrated, Fine Mycelium can also transform brands' supply chains with increased traceability, minimized waste and post processing, and a greatly enhanced sustainability profile.

MycoWorks announced its first partnership with Hermès in Spring of 2021 and has contracts in place with a range of major global luxury brands. MycoWorks is progressing towards entering the market at a range of price points as it moves into mass scale production.

About MycoWorks
In 2013, co-founders Philip Ross and Sophia Wang formed MycoWorks, a San Francisco-based biomaterials company dedicated to bringing new mycelium materials to the world. MycoWorks' patented Fine Mycelium technology, an advanced manufacturing platform and breakthrough in materials science, engineers mycelium during growth to form proprietary, interlocking cellular structures for unparalleled strength and durability.

About Prime Movers Lab
Prime Movers Lab invests in breakthrough scientific startups founded by Prime Movers, the inventors who transform billions of lives. Prime Movers Lab invests in companies reinventing energy, transportation, infrastructure, manufacturing, agriculture and human augmentation. Portfolio investments span in-space transportation, industrial solar heat, ag tech, brain upgrades, nano-structured materials, wafer slicing, prosthetics, 3D printing, mobility, longevity, and AI. For more information, please visit https://www.primemoverslab.com.

SOURCE MycoWorks